Researchers have tested a new combination of medications that could thwart resistance to common malaria drugs, significantly reducing the infection risk in pregnant women living with HIV.
A team of scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory and Columbia University has demonstrated a way to produce large quantities of the receptor that SARS-CoV-2, the virus that causes COVID-19, binds to on the surface of human cells.